134 related articles for article (PubMed ID: 11515856)
21. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
Konikoff MR; Denson LA
Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
[TBL] [Abstract][Full Text] [Related]
22. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.
Kristinsson J; Nygaard K; Aadland E; Barstad S; Sauar J; Hofstad B; Stray N; Stallemo A; Haug B; Ugstad M; Tøn H; Fuglerud P
Digestion; 2001; 64(2):104-10. PubMed ID: 11684824
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care.
Pavlidis P; Chedgy FJ; Tibble JA
Scand J Gastroenterol; 2013 Sep; 48(9):1048-54. PubMed ID: 23883068
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.
Holtman GA; Lisman-van Leeuwen Y; Kollen BJ; Norbruis OF; Escher JC; Kindermann A; de Rijke YB; van Rheenen PF; Berger MY
Ann Fam Med; 2016 Sep; 14(5):437-45. PubMed ID: 27621160
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin.
Schröder O; Naumann M; Shastri Y; Povse N; Stein J
Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510
[TBL] [Abstract][Full Text] [Related]
26. Comparative study of a new quantitative rapid test with an established ELISA method for faecal calprotectin.
Dolci A; Panteghini M
Clin Chim Acta; 2012 Jan; 413(1-2):350-1. PubMed ID: 21982915
[No Abstract] [Full Text] [Related]
27. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.
Kristensen V; Malmstrøm GH; Skar V; Røseth A; Moum B
Scand J Gastroenterol; 2016; 51(5):548-55. PubMed ID: 26634305
[TBL] [Abstract][Full Text] [Related]
28. Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives.
Chaabouni T; Manceau H; Peoc'h K
Ann Biol Clin (Paris); 2016 Aug; 74(4):385-94. PubMed ID: 27492691
[TBL] [Abstract][Full Text] [Related]
29. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases.
Diamanti A; Colistro F; Basso MS; Papadatou B; Francalanci P; Bracci F; Muraca M; Knafelz D; De Angelis P; Castro M
Inflamm Bowel Dis; 2008 Sep; 14(9):1229-35. PubMed ID: 18398894
[TBL] [Abstract][Full Text] [Related]
30. Faecal calprotectin: non-invasive marker of gastrointestinal inflammation in Salmonella infected rats.
Naughton PJ; Clohessy PA; Grant G; Pusztai A; Golden B
Biochem Soc Trans; 1996 May; 24(2):308S. PubMed ID: 8736966
[No Abstract] [Full Text] [Related]
31. Colonoscopy versus flexible sigmoidoscopy in evaluation of chronic diarrhea.
Srinivasan R; Friedel DM
Gastrointest Endosc; 2000 Oct; 52(4):589-90. PubMed ID: 11023595
[No Abstract] [Full Text] [Related]
32. Fecal biomarkers in inflammatory bowel disease.
Lopez RN; Leach ST; Lemberg DA; Duvoisin G; Gearry RB; Day AS
J Gastroenterol Hepatol; 2017 Mar; 32(3):577-582. PubMed ID: 27723123
[TBL] [Abstract][Full Text] [Related]
33. Fecal calprotectin in inflammatory bowel diseases: update and perspectives.
Manceau H; Chicha-Cattoir V; Puy H; Peoc'h K
Clin Chem Lab Med; 2017 Mar; 55(4):474-483. PubMed ID: 27658156
[TBL] [Abstract][Full Text] [Related]
34. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
35. Colonoscopy and SeHCAT for investigation of chronic diarrhea.
Müller M; Willén R; Stotzer PO
Digestion; 2004; 69(4):211-8. PubMed ID: 15205569
[TBL] [Abstract][Full Text] [Related]
36. [Diagnostic strategy for chronic diarrhea in adults].
Cerf M
Gastroenterol Clin Biol; 1992; 16(2 ( Pt 3)):T12-21. PubMed ID: 1563605
[No Abstract] [Full Text] [Related]
37. High prevalence of NSAID enteropathy as shown by a simple faecal test.
Tibble JA; Sigthorsson G; Foster R; Scott D; Fagerhol MK; Roseth A; Bjarnason I
Gut; 1999 Sep; 45(3):362-6. PubMed ID: 10446103
[TBL] [Abstract][Full Text] [Related]
38. Fecal calprotectin: towards a standardized use for inflammatory bowel disease management in routine practice.
Louis E
J Crohns Colitis; 2015 Jan; 9(1):1-3. PubMed ID: 25536671
[No Abstract] [Full Text] [Related]
39. [Fecal Calprotectin in Inflammatory Bowel Disease].
Lee J
Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
[TBL] [Abstract][Full Text] [Related]
40. Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea.
Licata A; Randazzo C; Cappello M; Calvaruso V; Butera G; Florena AM; Peralta S; Cammà C; Craxì A
J Clin Gastroenterol; 2012 Jul; 46(6):504-8. PubMed ID: 22565607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
